Ardelyx Addresses Zydus Acquisition Rumors: No Comment on Business Development

• US biopharmaceutical firm Ardelyx acknowledged reports regarding Zydus Lifesciences but declined to comment on business development activities.
• This response follows CNBC-TV18 reports on January 20 that Zydus Lifesciences is in talks to acquire Ardelyx.
• Sources suggest Zydus may acquire a controlling stake or select molecules from Ardelyx, which has a market capitalization of approximately $1.6 billion.
• Zydus Lifesciences is considering a Qualified Institutional Placement (QIP) to help fund the potential acquisition, having previously approved raising up to ₹5,000 crore.
• Ardelyx has two commercial products in the US: IBSRELA for IBS with constipation and XYPHOZAH for chronic kidney disease.

Why It Matters: Ardelyx remains tight-lipped on Zydus acquisition rumors, while Zydus explores funding options.